OTCMarketsExpert

$LIXT 40% MORE UPSIDE IN LIXTE BIOTECHNOLOGY

Long
OTC:LIXT   None
COMPANY PROFILE
Lixte Biotechnology Holdings, Inc. engages in the development of drugs for cancer treatment. It uses biomarker technology to identify enzyme targets associated with serious common diseases and designs novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in East Setauket, NY.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.